Targeting prostate cancer cells in vivo using a rapidly internalizing novel human single-chain antibody fragment

Journal of Nuclear Medicine

Volumn 51, Issue 3, 2010, Pages 427-432

  He, Jiang ^a,b   Wang, Yong ^c   Feng, Jinjin ^a   Zhu, Xiaodong ^c   Lan, Xiaoli ^a   Iyer, Arun K ^a   Zhang, Niu ^c   Seo, Youngho ^a   VanBrocklin, Henry F ^a,b   Liu, Bin ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody fragment; Molecular imaging; Prostate cancer

Indexed keywords

SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY N3M2; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY UA20 TECHNETIUM TC 99M; TECHNETIUM 99M; UNCLASSIFIED DRUG; IMMUNOGLOBULIN FRAGMENT; TECHNETIUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CONTROLLED STUDY; KIDNEY TUBULE ABSORPTION; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE TUMOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; KINETICS; METABOLISM; PATHOLOGY; PROTEIN TRANSPORT; RADIOGRAPHY; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; HUMANS; IMMUNOGLOBULIN FRAGMENTS; KINETICS; MALE; MICE; ORGANOTECHNETIUM COMPOUNDS; PROSTATIC NEOPLASMS; PROTEIN TRANSPORT; SINGLE-CHAIN ANTIBODIES; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77950363062     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.069492     Document Type: Article

References (40)

1. Ravizzini G, Turkbey B, Kurdziel K, Choyke PL. New horizons in prostate cancer imaging. Eur J Radiol. 2009;70:212-226.
2. Bander NH. Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol. 2006;3:216-225.
3. Sodee DB, Ellis RJ, Samuels MA. Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results. Prostate. 1998;37:140-148.
4. Milowsky MI, Nanus DM, Kostakoglu L. Vascular targeted therapy with antiprostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol. 2007;25:540-547. (Pubitemid 350002961)
5. Zhou J, Neale JH, Pomper MG, Kozikowski AP. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Natl Rev Drug Discov. 2005;4:1015-1026.
6. 99mTc preloading strategy. J Nucl Med. 2007;48:1379-1389.
7. Tang H, Brown M, Ye Y. Prostate targeting ligands based on N-acetylated α-linked acidic dipeptidase. Biochem Biophys Res Commun. 2003;307:8-14. (Pubitemid 36808529)
8. Humblet V, Lapidus R, Williams L. High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen. Mol Imaging. 2005;4:448-462. (Pubitemid 43143785)
9. Liu T, Wu L, Kazak M, Berkman CE. Cell-surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen. Prostate. 2008;68:955-964. (Pubitemid 351794160)
10. 18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res. 2008;14:3036-3043.
11. Banerjee SR, Foss AC, Castanares M. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem. 2008;51:4504-4517.
12. Chen Y, Foss CA, Byun Y. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem. 2008;51:7933-7943.
13. Foss CA, Mease RC, Fan H, et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res. 2005;11:4022-4028. (Pubitemid 40791565)
14. 11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol Imaging. 2002;1:96-101.
15. Els̈asser-Beile U, Reischl G, Wiehr S, et al. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J Nucl Med. 2009;50:606-611.
16. 177Lu-7E11 radioimmunotherapy. Mol Imaging Biol. 2009;11:159-166.
17. 90Y radioimmunotherapy. J Nucl Med. 2008;49:1066-1074.
18. 111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res. 2005;11:7454-7461.
19. Lam JS, Yamashiro J, Shintaku IP, et al. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res. 2005;11:2591-2596. (Pubitemid 40569458)
20. Olafsen T, Kenanova VE, Wu AM. Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat Protoc. 2006;1:2048-2060. (Pubitemid 46773329)
21. Olafsen T, Gu Z, Sherman MA, et al. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother. 2007;30:396-405. (Pubitemid 46684429)
22. Leyton JV, Olafsen T, Lepin EJ, et al. Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clin Cancer Res. 2008;14:7488-7496.
23. Leyton JV, Olafsen T, Sherman MA, et al. Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. Protein Eng Des Sel. 2009;22:209-216.
24. Parry R, Schneider D, Hudson D, et al. Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer. Cancer Res. 2005;65:8397-8405. (Pubitemid 41330606)
25. 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice. J Nucl Med. 2009;50:435-443.
26. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001;61:4750-4755.
27. Ruan W, Sassoon A, An F, Simko JP, Liu B. Identification of clinically significant tumor antigens by selecting phage antibody library on tumor cells in situ using laser capture microdissection. Mol Cell Proteomics. 2006;5:2364-2373.
28. Roth A, Drummond DC, Conrad F, et al. Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther. 2007;6:2737-2746. (Pubitemid 350058154)
29. An F, Drummond DC, Wilson S, et al. Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies. Mol Cancer Ther. 2008;7:569-578.
30. Nielsen UB, Kirpotin DB, Pickering EM, et al. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta. 2002;1591:109-118.
31. Liu B, Conrad F, Cooperberg MR, Kirpotin DB, Marks JD. Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res. 2004;64:704-710.
32. Waibel R, Alberto R, Willuda J, et al. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat Biotechnol. 1999;17:897-901.
33. Bidlingmaier S, He J, Wang Y, et al. Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma. Cancer Res. 2009;69:1570-1577.
34. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77-89.
35. Wu AM, Chen W, Raubitschek A, et al. Tumor localization of anti-CEA singlechain Fvs: improved targeting by non-covalent dimers. Immunotechnology. 1996;2:21-36. (Pubitemid 26096269)
36. 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. J Nucl Med. 2009;50:781-789.
37. 68Ga for PET imaging of HER2 expression. J Nucl Med. 2009;50:1492-1499.
38. Bidlingmaier S, Liu B. Interrogating yeast surface-displayed human proteome to identify small molecule-binding proteins. Mol Cell Proteomics. 2007;6:2012-2020. (Pubitemid 350201874)
39. Bidlingmaier S, Liu B. Construction and application of a yeast surface-displayed human cDNA library to identify post-translational modification-dependent protein-protein interactions. Mol Cell Proteomics. 2006;5:533-540.
40. Conrad F, Zhu X, Zhang X, et al. Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion. J Mol Med. 2009;87:507-514.